

Choroidal neovascularization Myopia

**A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia**

**Trial Status**  
Recruiting

**Trial Runs In**  
12 Countries

**Trial Identifier**  
NCT06176352 2023-506707-25-00  
CR44829

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT06176352 2023-506707-25-00 CR44829**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---